Novel Peptide Vaccination for Patients With Advanced Bladder Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2010

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

MPHOSPH1 and DEPDC1

DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.

Trial Locations (1)

020-8505

Iwate Medical University School of Medicine, Morioka

All Listed Sponsors
collaborator

Human Genome Center, Institute of Medical Science, University of Tokyo

OTHER

lead

Iwate Medical University

OTHER

NCT00635336 - Novel Peptide Vaccination for Patients With Advanced Bladder Cancer | Biotech Hunter | Biotech Hunter